{"organizations": [], "uuid": "16e70729ee8445f74605c614b197b7577d11f97a", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180424.html", "section_title": "Archive News &amp; Video for Tuesday, 24 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-checkmate-pharmaceuticals-announce/brief-checkmate-pharmaceuticals-announces-start-of-phase-1b-trial-of-cmp-001-in-combination-with-anti-pd-l1-immunotherapy-in-anti-pd-1-pd-l1-resistant-advanced-non-small-cell-lung-cancer-idUSASC09WZP", "country": "US", "domain_rank": 408, "title": "BRIEF-Checkmate Pharmaceuticals Announces Start Of Phase 1B Trial Of CMP-001 In Combination With Anti-Pd-L1 Immunotherapy In Anti-Pd-1/Pd-L1 Resistant Advanced Non-Small Cell Lung Cancer", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.426, "site_type": "news", "published": "2018-04-24T19:12:00.000+03:00", "replies_count": 0, "uuid": "16e70729ee8445f74605c614b197b7577d11f97a"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-checkmate-pharmaceuticals-announce/brief-checkmate-pharmaceuticals-announces-start-of-phase-1b-trial-of-cmp-001-in-combination-with-anti-pd-l1-immunotherapy-in-anti-pd-1-pd-l1-resistant-advanced-non-small-cell-lung-cancer-idUSASC09WZP", "ord_in_thread": 0, "title": "BRIEF-Checkmate Pharmaceuticals Announces Start Of Phase 1B Trial Of CMP-001 In Combination With Anti-Pd-L1 Immunotherapy In Anti-Pd-1/Pd-L1 Resistant Advanced Non-Small Cell Lung Cancer", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "neutral"}, {"name": "thomson reuters trust principles", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " CHECKMATE PHARMACEUTICALS:\n* CHECKMATE PHARMACEUTICALS ANNOUNCES START OF PHASE 1B TRIAL OF CMP-001 IN COMBINATION WITH ANTI-PD-L1 IMMUNOTHERAPY IN ANTI-PD-1/PD-L1 RESISTANT ADVANCED NON-SMALL CELL LUNG CANCER Source text for Eikon: (Reuters.Briefs@thomsonreuters.com)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-04-24T19:12:00.000+03:00", "crawled": "2018-04-25T14:28:12.009+03:00", "highlightTitle": ""}